<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490983</url>
  </required_header>
  <id_info>
    <org_study_id>RexCCWF1</org_study_id>
    <nct_id>NCT01490983</nct_id>
  </id_info>
  <brief_title>Telemonitoring Study - for Chronic Myeloid Leukemia (CML)</brief_title>
  <official_title>Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Nilotinib) Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rex Cancer Center, Raleigh, NC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leap of Faith Technologies</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rex Cancer Center, Raleigh, NC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted in a population of patients with chronic phase Chronic Myeloid
      Leukemia (CML) to learn more about how patients follow prescribed regimens for taking oral
      cancer drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, controlled pilot study to introduce eMedonline telemonitoring
      technology to CML patients taking Gleevec or Tasigna. eMedonline will be used to
      automatically collect time-dose specific medication data for individual patients, including
      dosing times, missed doses, adverse events and e-diary data. All data will be available to
      research staff for remote review via Web interface. Adverse events and non-adherence will
      prompt interventions including supportive care counseling.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>eMedonline will be used to measure non-compliance in taking oral drug regimens.</measure>
    <time_frame>at 6 months, non-compliance will be measured in each arm of study</time_frame>
    <description>Patients are stratified to one of two groups: Group 1 is patients on Gleevec or Tasigna who have been on drug less than 6 months; Group 2 is patients on Gleevec or Tasigna who have been on drug for equal to or more than 6 months.
Group 1 is then divided into 2 groups: one using eMedonline for 3 months and the other not using eMedonline for 3 months. A crossover survey and pill counts will be done at the 3 month timepoint and then the groups will switch their access status to eMedonline.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>eMedonline access</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will have access to eMedonline access for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no access to eMedonline</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients will be followed for 3 months with no access to eMedonline</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>no access to eMedonline</intervention_name>
    <description>patients will be followed for 3 months but will not use eMedonline</description>
    <arm_group_label>no access to eMedonline</arm_group_label>
    <other_name>Telemonitoring system</other_name>
    <other_name>e-diary</other_name>
    <other_name>electronic diary</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>eMedonline access</intervention_name>
    <description>patients will be given access to eMedonline use for 3 months</description>
    <arm_group_label>eMedonline access</arm_group_label>
    <other_name>Telemonitoring system</other_name>
    <other_name>e-diary</other_name>
    <other_name>electronic diary</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years of age or older.

          -  Pathologically documented diagnosis of Chronic Phase CML (Ph+) in whom treating
             physician has determined that treatment with imatinib or nilotinib is appropriate

          -  Patients currently receiving Gleevec (imatinib) 300-600 mg daily or Tasigna
             (nilotinib) 300-400 mg twice daily

          -  ECOG Performance status 0, 1, or 2

          -  Adequate end organ function, defined as:

               -  Total bilirubin &lt; 1.5 xULN

               -  SGOT and SGPT &lt;2.5 x ULN

               -  Creatinine &lt; 1.5 x ULN

               -  ANC &gt; 1.5

               -  Platelets &gt; 100,000

          -  Female patients of child bearing potential must have a negative urine or serum
             pregnancy test at screening.

          -  Patient is able to read and speak English

          -  Patient is willing and able to use a cell phone

          -  Written, voluntary informed consent

        Exclusion Criteria:

          -  Patient with any significant history of non-compliance to medical regimens or with
             inability to grant reliable informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Wehbie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rex Cancer Center - Wakefield</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNC Healthcare</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rex Cancer Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rex Cancer Center - Wakefield</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2011</study_first_submitted>
  <study_first_submitted_qc>December 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2011</study_first_posted>
  <last_update_submitted>April 7, 2016</last_update_submitted>
  <last_update_submitted_qc>April 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Myeloid Leukemia</keyword>
  <keyword>Chronic Phase CML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

